Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Salvage Followed by CAR-T +/- ASCT in R/R Aggressive B-Cell Lymphoma
NCT06996132Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in aggressive B-cell lymphoma, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete Response Rate after CAR-T±ASCT at 1 year. Started May 2025; status: recruiting.
02
Drugs
glofitamab
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT06996132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06996132.